This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I) ##STR00001## wherein ##STR00002## Q, J, L and Z are as defined in the specification.
Claims What is claimed is: 1. A compound of Formula (IV) or pharmaceutically acceptable salt thereof: ##STR00833## wherein: R.sup.140 is selected from the group consisting of: H, --OH, halo, --CN, --C.sub.1-C.sub.4alkyl, --C.sub.1-C.sub.4alkoxyl, --O--C.sub.2-C.sub.4alkyl-O--C.sub.1-C.sub.4alkyl, --CF.sub.3, --OCF.sub.3, --NO.sub.2, --C.sub.1-C.sub.6alkyl-S(O).sub.0-2R.sup.53, --NH.sub.2, --NR.sup.50R.sup.51, --C.sub.1-C.sub.6alkyl-NR.sup.50R.sup.51 and --N(C.sub.1-C.sub.6alkyl).sub.2; xa and xb denote numbers that are each independently selected from 0, 1 and 2; R.sup.150 and a R.sup.160 independently selected from the group consisting of H, halo, --CN, --CF.sub.3, --OCF.sub.3, --C.sub.1-C.sub.6alkyl, --C.sub.1-C.sub.6alkoxyl, --O--C.sub.2-C.sub.6alkyl-O--R.sup.53, --OR.sup.53, --C.sub.0-C.sub.6alkyl-S(O).sub.0-2--R.sup.53, --C.sub.0-C.sub.6alkyl-C(O)--R.sup.53, --C.sub.0-C.sub.6alkyl-C(O)NR.sup.50R.sup.51, --C.sub.0-C.sub.6alkyl-NR.sup.52C(O)--R.sup.53, --C.sub.0-C.sub.6alkyl -S(O).sub.2NR.sup.50R.sup.51, --C.sub.0-C.sub.6alkyl-NR.sup.52S(O).sub.2--R.sup.53, --C.sub.0-C.sub.6alkyl-OC(O)NR.sup.50R.sup.51, --C.sub.0-C.sub.6alkyl -NR.sup.52C(O)O--R.sup.53, --C.sub.0-C.sub.6alkyl-NR.sup.52C(O)NR.sup.50R.sup.51, --C.sub.0-C.sub.6alkyl-C(O)O--R.sup.53, --C.sub.0-C.sub.6alkyl -OC(O)--R.sup.53, --C.sub.0-C.sub.6alkyl-aryl, --C.sub.0-C.sub.6alkyl-heteroaryl, --C.sub.0-C.sub.6alkyl-cycloalkyl, --C.sub.0-C.sub.6alkyl -heterocyclyl, --NH.sub.2, --NR.sup.50R.sup.51, --C.sub.1-C.sub.6alkyl-NR.sup.50R.sup.51, --O--C.sub.2-C.sub.6alkyl-NR.sup.50R.sup.51, --NR.sup.53--C.sub.2-C.sub.6alkyl-NR.sup.50R.sup.51 and --O-heterocyclyl-R.sup.53, wherein each alkyl and heteroalkyl is optionally substituted with one or three substituents independently selected from the group consisting of F, --OH and oxo, and wherein each aryl, heteroaryl, cycloalkyl and heterocyclyl is optionally substituted with one or two substituents independently selected from the group consisting of halo, --CN, --C.sub.1-C.sub.4alkyl, --C.sub.1-C.sub.4alkoxyl, --O--C.sub.2-C.sub.4alkyl-O--C.sub.1-C.sub.4alkyl, --CF.sub.3, --OCF.sub.3, --NO.sub.2, --C.sub.1-C.sub.6alkyl-S(O).sub.0-2R.sup.53, --NH.sub.2, --NR.sup.50R.sup.51, --C.sub.1-C.sub.6alkyl-NR.sup.50R.sup.51 and --N(C.sub.1-C.sub.6alkyl).sub.2; R.sup.50 and R.sup.51 are independently selected from the group consisting of H, --C.sub.1-C.sub.6alkyl, --C.sub.2-C.sub.6alkyl -O--C.sub.1-C.sub.6alkyl, --C.sub.0-C.sub.6alkyl-C.sub.3-C.sub.7cycloalkyl, wherein each alkyl and cycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of halo, --OH, amino, --CN or --C.sub.1-C.sub.4alkyl; or R.sup.50 and R.sup.51, together with the N atom to which they are attached, optionally form a 3-10 membered heterocyclic ring, wherein the heterocyclyl is optionally substituted with one to three substituents independently selected from the group consisting of halo, --OH, amino, --CN or --C.sub.1-C.sub.4alkyl; R.sup.52 is independently selected from the group consisting of --H, --C.sub.1-C.sub.6alkyl, --C.sub.2-C.sub.6alkyl-O--C.sub.1-C.sub.6alkyl, --C.sub.0-C.sub.6alkyl-C.sub.3-C.sub.7cycloalkyl, wherein each alkyl and cycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of halo, --OH, amino, --CN or --C.sub.1-C.sub.4alkyl; and R.sup.53 is independently selected from the group consisting of --C.sub.1-C.sub.6alkyl, --C.sub.0-C.sub.4alkyl-C.sub.3-C.sub.7cycloalkyl, --C.sub.0-C.sub.4alkyl-aryl, --C.sub.0-C.sub.4alkyl-heteroaryl and --C.sub.0-C.sub.4alkyl-heterocyclyl, wherein each alkyl, aryl, heteroaryl and heterocyclyl is optionally substituted with one or three substituents independently selected from the group consisting of halo, --OH, amino, --CN or --C.sub.1-C.sub.4alkyl. 2. The compound of claim 1 or a pharmaceutically acceptable salt thereof having Formula V: ##STR00834## wherein: xc is 0 or 1; and R.sup.170 is selected from the group consisting of H, halo, --CN, --CF.sub.3, --OCF.sub.3, --C.sub.1-C.sub.6alkyl, --C.sub.1-C.sub.6alkoxyl, --O--C.sub.2-C.sub.6alkyl-O--R.sup.53, --OR.sup.53, --C.sub.0-C.sub.6alkyl-S(O).sub.0-2--R.sup.53, --C.sub.0-C.sub.6alkyl-C(O)--R.sup.53, --C.sub.0-C.sub.6alkyl-C(O)NR.sup.50R.sup.51, --C.sub.0-C.sub.6alkyl-NR.sup.52C(O)--R.sup.53, --C.sub.0-C.sub.6alkyl-S(O).sub.2NR.sup.50R.sup.51, --C.sub.0-C.sub.6alkyl -NR.sup.52S(O).sub.2--R.sup.53, --C.sub.0-6alkyl-OC(O)NR.sup.50R.sup.51, --C.sub.0-C.sub.6alkyl-NR.sup.52C(O)O--R.sup.53, --C.sub.0-C.sub.6alkyl -NR.sup.52C(O)NR.sup.50R.sup.51, --C.sub.0-C.sub.6alkyl-C(O)O--R.sup.53, --C.sub.0-C.sub.6alkyl-OC(O)--R.sup.53, --C.sub.0-C.sub.6alkyl-aryl, --C.sub.0-C.sub.6alkyl-heteroaryl, --C.sub.0-C.sub.6alkyl-cycloalkyl, --C.sub.0-C.sub.6alkyl-heterocyclyl, --NH.sub.2, --NR.sup.50R.sup.51, --C.sub.1-C.sub.6alkyl-NR.sup.50R.sup.51, --O--C.sub.2-C.sub.6alkyl-NR.sup.50R.sup.51, --NR.sup.53--C.sub.2-C.sub.6alkyl-NR.sup.50R.sup.51 and --O-heterocyclyl -R.sup.53, wherein each alkyl and heteroalkyl is optionally substituted with one or three substituents independently selected from the group consisting of F, --OH and oxo, wherein each aryl, heteroaryl, cycloalkyl and heterocyclyl is optionally substituted with one or two substituents independently selected from the group consisting of halo, --CN, --C.sub.1-C.sub.4alkyl, --C.sub.1-C.sub.4alkoxyl, --O--C.sub.2-C.sub.4alkyl-O--C.sub.1-C.sub.4alkyl, --CF.sub.3, --OCF.sub.3, --NO.sub.2, --C.sub.1-C.sub.6alkyl-S(O).sub.0-2R.sup.53, --NH.sub.2, --NR.sup.50R.sup.51, --C.sub.1-C.sub.6alkyl-NR.sup.50R.sup.51 and --N(C.sub.1-C.sub.6alkyl).sub.2. 3. The compound of claim 2 or a pharmaceutically acceptable salt thereof having Formula (VI): ##STR00835## 4. A compound or a pharmaceutically acceptable salt thereof selected from the group consisting of: (Z)-4-(dibenzo [b,f][1,4]oxazepin-11-yl)-N-hydroxybenzamide, 4-(10,11-dihydrodibenzo[b,f][1,4]oxazepin-11-yl)-N-hydroxybenzamide, N-hydroxy-4-(10-methyl-10,11-dihydrodibenzo[b,f][1,4]oxazepin-11-yl)benza- mide, (Z)-4-(2-fluorodibenzo[b,f][1,4]oxazepin-11-yl)-N-hydroxybenzamide, (Z)--N-hydroxy-4-(2-methoxydibenzo[b,f][1,4]oxazepin-11-yl)benzamide, (Z)-4-(2-(2-(dimethylamino)ethoxy)dibenzo[b,f][1,4]oxazepin- 11-yl)-N-hydroxybenzamide, (Z)--N-hydroxy-4-(8-(trifluoromethyl)dibenzo[b,f][1,4]oxazepin-11 -yl)benzamide, (Z)-4-(dibenzo[b,f][1,4]oxazepin-11-yl)-2-fluoro-N-hydroxybenzamide, (Z)--N-hydroxy-4-(3-methoxydibenzo[b,f][1,4]oxazepin-11-yl)benzamide, (Z)-3-(dibenzo[b,f][1,4]oxazepin-11-yl)-N-hydroxybenzamide, (Z)--N-hydroxy-4-(8-methyldibenzo[b,f][1,4]oxazepin-11-yl)benzamide, (Z)--N-hydroxy-4-(4-methoxydibenzo[b,f][1,4]oxazepin-11-yl)benzamide, (Z)-4-(9-fluorodibenzo[b,f][1,4]oxazepin-11-yl)-N-hydroxybenzamide, (Z)--N-hydroxy-4-(7-(trifluoromethyl)dibenzo[b,f][1,4]oxazepin-11 -yl)benzamide, (Z)-4-(7-chlorodibenzo[b,f][1,4]oxazepin-11-yl)-N-hydroxybenzamide, (Z)-4-(2-chlorodibenzo[b,f][1,4]oxazepin-11-yl)-N-hydroxybenzamide, (Z)-4-(8-cyanodibenzo[b,f][1,4]oxazepin-11-yl)-N-hydroxybenzamide, (Z)--N-hydroxy-4-(4-methyldibenzo[b,f][1,4]oxazepin-11-yl)benzamide, (Z)--N-hydroxy-4-(3-methyldibenzo[b,f][1,4]oxazepin-11-yl)benzamide, (Z)-4-(3-fluorodibenzo[b,f][1,4]oxazepin-11-yl)-N-hydroxybenzamide, (Z)-4-(8-chlorodibenzo[b,f][1,4]oxazepin-11-yl)-N-hydroxybenzamide, (Z)--N-hydroxy-4-(3-(trifluoromethyl)dibenzo[b,f][1,4]oxazepin- 11-yl)benzamide, (Z)-4-(6-fluorodibenzo[b,f][1,4]oxazepin-11-yl)-N-hydroxybenzamide, (Z)-4-(7-cyanodibenzo[b,f][1,4]oxazepin-11-yl)-N-hydroxybenzamide, (Z)--N-hydroxy-4-(4-hydroxydibenzo[b,f][1,4]oxazepin-11-yl)benzamide, (Z)--N-hydroxy-4-(1-methoxydibenzo[b,f][1,4]oxazepin-11-yl)benzamide, (Z)--N-hydroxy-4-(4-(2-methoxyethoxy)dibenzo[b,f][1,4]oxazepin-11-yl)benz- amide, (Z)-4-(1-fluorodibenzo[b,f][1,4]oxazepin-11-yl)-N-hydroxybenzamide, (Z)--N-hydroxy-4-(4-(2-morpholinoethoxy)dibenzo[b,f][1,4]oxazepin-11-yl)b- enzamide, (Z)-4-(2-fluoro-4-methoxydibenzo[b,f][1,4]oxazepin-11-yl)-N-hydr- oxybenzamide, (Z)--N-hydroxy-4-(4-(methylthio)dibenzo[b,f][1,4]oxazepin-11-yl)benzamide- , (Z)--N-hydroxy-4-(4-(trifluoromethyl)dibenzo[b,f][1,4]oxazepin- 11-yl)benzamide, (Z)--N-hydroxy-4-(4-(methylsulfinyl)dibenzo[b,f][1,4]oxazepin-11-yl)benza- mide, (Z)--N-hydroxy-4-(4-(methylsulfonyl)dibenzo[b,f][1,4]oxazepin-11-yl)- benzamide, (E)-4-((dibenzo[b,f][1,4]oxazepin-11-ylamino)methyl)-N-hydroxyb- enzamide, (Z)--N-hydroxy-4-(4-methoxy-8-(trifluoromethyl)dibenzo[b,f][1,4]- oxazepin-11-yl)benzamide, (Z)--N-hydroxy-4-(3-morpholinodibenzo[b,f][1,4]oxazepin-11-yl)benzamide, (Z)--N-hydroxy-4-(4-propyldibenzo[b,f][1,4]oxazepin-11-yl)benzamide, (Z)--N-hydroxy-4-(4-(trifluoromethoxy)dibenzo[b,f][1,4]oxazepin- 11-yl)benzamide, (Z)--N-hydroxy-4-(6-methyldibenzo[b,f][1,4]oxazepin-11-yl)benzamide, (E)-4-(dibenzo[b,f][1,4]oxazepin-11-yl)-3-fluoro-N-hydroxybenzamide, (Z)-4-(4-fluorodibenzo[b,f][1,4]oxazepin-11-yl)-N-hydroxybenzamide, and (E)-4-(2-(dibenzo[b,f][1,4]oxazepin-11-ylamino)ethyl)-N-hydroxybenzamide. 5. A pharmaceutical composition comprising the compound of any of claims 1-4 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. 6. A method for alleviating one or more symptoms of Huntington's Disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any of claims 1-4 or a pharmaceutically acceptable salt thereof. 7. A method for alleviating one or more symptoms of dentatorubralpallidoluysian atrophy comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any of claims 1-4 or a pharmaceutically acceptable salt thereof. 8. A method for alleviating one or more symptoms of spinocerebellar ataxia type 3 comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any of claims 1-4 or a pharmaceutically acceptable salt thereof. 9. A method for alleviating one or more symptoms of spinal bulbar muscular atrophy comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any of claims 1-4 or a pharmaceutically acceptable salt thereof. 10. The compound of claim 4 wherein the compound is (Z)-4-(dibenzo[b,f][1,4]oxazepin-11-yl)-N-hydroxybenzamide, or a pharmaceutically acceptable salt thereof. 11. The compound of claim 4 wherein the compound is 4-(10,11-dihydrodibenzo[b,f][1,4]oxazepin-11-yl)-N-hydroxybenzamide, or a pharmaceutically acceptable salt thereof. 12. The compound of claim 4 wherein the compound is N-hydroxy-4-(10-methyl-10,11-dihydrodibenzo[b,f][1,4]oxazepin-11-yl)benza- mide, or a pharmaceutically acceptable salt thereof. 13. The compound of claim 4 wherein the compound is (Z)-4-(2-fluorodibenzo[b,f][1,4]oxazepin-11-yl)-N-hydroxybenzamide, or a pharmaceutically acceptable salt thereof. 14. The compound of claim 4 wherein the compound is (Z)-N-hydroxy-4-(2-methoxydibenzo[b,f][1,4]oxazepin-11-yl)benzamide, or a pharmaceutically acceptable salt thereof. 15. The compound of claim 4 wherein the compound is (Z)-4-(2-(2-(dimethylamino)ethoxy)dibenzo[b,f][1,4]oxazepin-11-yl)-N-hydr- oxybenzamide, or a pharmaceutically acceptable salt thereof. 16. The compound of claim 4 wherein the compound is (Z)-N-hydroxy-4-(8-(trifluoromethyl)dibenzo[b,f][1,4]oxazepin-11-yl)benza- mide, or a pharmaceutically acceptable salt thereof. 17. The compound of claim 4 wherein the compound is (Z)-4-(dibenzo[b,f][1,4]oxazepin-11-yl)-2-fluoro-N-hydroxybenzamide, or a pharmaceutically acceptable salt thereof. 18. The compound of claim 4 wherein the compound is (Z)-N-hydroxy-4-(3-methoxydibenzo[b,f][1,4]oxazepin-11-yl)benzamide, or a pharmaceutically acceptable salt thereof. 19. The compound of claim 4 wherein the compound is (Z)-3-(dibenzo[b,f][1,4]oxazepin-11-yl)-N-hydroxybenzamide, or a pharmaceutically acceptable salt thereof. 20. The compound of claim 4 wherein the compound is (Z)-N-hydroxy-4-(8-methyldibenzo[b,f][1,4]oxazepin-11-yl)benzamide, or a pharmaceutically acceptable salt thereof. 21. The compound of claim 4 wherein the compound is (Z)-N-hydroxy-4-(4-methoxydibenzo[b,f][1,4]oxazepin-11-yl)benzamide, or a pharmaceutically acceptable salt thereof. 22. The compound of claim 4 wherein the compound is (Z)-4-(9- fluorodibenzo[b,f][1,4]oxazepin-11-yl)-N-hydroxybenzamide, or a pharmaceutically acceptable salt thereof. 23. The compound of claim 4 wherein the compound is (Z)-N-hydroxy-4-(7-(trifluoromethyl)dibenzo[b,f][1,4]oxazepin-11-yl)benza- mide, or a pharmaceutically acceptable salt thereof. 24. The compound of claim 4 wherein the compound is (Z)4-(7-chlorodibenzo[b,f][1,4]oxazepin-11-yl)-N-hydroxybenzamide, or a pharmaceutically acceptable salt thereof. 25. The compound of claim 4 wherein the compound is (Z)-4-(2-chlorodibenzo[b,f][1,4]oxazepin-11-yl)-N-hydroxybenzamide, or a pharmaceutically acceptable salt thereof. 26. The compound of claim 4 wherein the compound is (Z)-4-(8-cyanodibenzo[b,f][1,4]oxazepin-11-yl)-N-hydroxybenzamide, or a pharmaceutically acceptable salt thereof. 27. The compound of claim 4 wherein the compound is (Z)-N-hydroxy-4-(4-methyldibenzo[b,f][1,4]oxazepin-11-yl)benzamide, or a pharmaceutically acceptable salt thereof. 28. The compound of claim 4 wherein the compound is (Z)-N-hydroxy-4-(3-methyldibenzo[b,f][1,4]oxazepin-11-yl)benzamide, or a pharmaceutically acceptable salt thereof. 29. The compound of claim 4 wherein the compound is (Z)-4-(3-fluorodibenzo[b,f][1,4]oxazepin-11-yl)-N-hydroxybenzamide, or a pharmaceutically acceptable salt thereof. 30. The compound of claim 4 wherein the compound is (Z)-4-(8-chlorodibenzo[b,f][1,4]oxazepin-11-yl)-N-hydroxybenzamide, or a pharmaceutically acceptable salt thereof. 31. The compound of claim 4 wherein the compound is (Z)-N-hydroxy-4-(3-(trifluoromethyl)dibenzo[b,f][1,4]oxazepin-11-yl)benza- mide, or a pharmaceutically acceptable salt thereof. 32. The compound of claim 4 wherein the compound is (Z)-4-(6-fluorodibenzo[b,f][1,4]oxazepin-11-yl)-N-hydroxybenzamide, or a pharmaceutically acceptable salt thereof. 33. The compound of claim 4 wherein the compound is (Z)-4-(7-cyanodibenzo[b,f][1,4]oxazepin-11-yl)-N-hydroxybenzamide, or a pharmaceutically acceptable salt thereof. 34. The compound of claim 4 wherein the compound is (Z)-N-hydroxy-4-(4-hydroxydibenzo[b,f][1,4]oxazepin-11-yl)benzamide, or a pharmaceutically acceptable salt thereof. 35. The compound of claim 4 wherein the compound is (Z)-N-hydroxy-4-(1-methoxydibenzo[b,f][1,4]oxazepin-11-yl)benzamide, or a pharmaceutically acceptable salt thereof. 36. The compound of claim 4 wherein the compound is (Z)-N-hydroxy-4-(4-(2-methoxyethoxy)dibenzo[b,f][1,4]oxazepin-11-yl)benza- mide, or a pharmaceutically acceptable salt thereof. 37. The compound of claim 4 wherein the compound is (Z)-4-(1-fluorodibenzo[b,f][1,4]oxazepin-11-yl)-N-hydroxybenzamide, or a pharmaceutically acceptable salt thereof. 38. The compound of claim 4 wherein the compound is (Z)-N-hydroxy-4-(4-(2-morpholinoethoxy)dibenzo[b,f][1,4]oxazepin-11-yl)be- nzamide, or a pharmaceutically acceptable salt thereof. 39. The compound of claim 4 wherein the compound is (Z)-4-(2-fluoro-4-methoxydibenzo[b,f][1,4]oxazepin-11-yl)-N-hydroxybenzam- ide, or a pharmaceutically acceptable salt thereof. 40. The compound of claim 4 wherein the compound is (Z)-N-hydroxy-4-(4-(methylthio)dibenzo[b,f][1,4]oxazepin-11-yl)benzamide, or a pharmaceutically acceptable salt thereof. 41. The compound of claim 4 wherein the compound is (Z)-N-hydroxy-4-(4-(trifluoromethyl)dibenzo[b,f][1,4]oxazepin-11-yl)benza- mide, or a pharmaceutically acceptable salt thereof. 42. The compound of claim 4 wherein the compound is (Z)-N-hydroxy-4-(4-(methylsulfinyl)dibenzo[b,f][1,4]oxazepin-11-yl)benzam- ide, or a pharmaceutically acceptable salt thereof. 43. The compound of claim 4 wherein the compound is (Z)-N-hydroxy-4-(4-(methylsulfonyl)dibenzo[b,f][1,4]oxazepin-11-yl)benzam- ide, or a pharmaceutically acceptable salt thereof. 44. The compound of claim 4 wherein the compound is (E)-4-((dibenzo[b,f][1,4]oxazepin-11-ylamino)methyl)-N-hydroxybenzamide, or a pharmaceutically acceptable salt thereof. 45. The compound of claim 4 wherein the compound is (Z)-N-hydroxy-4-(4-methoxy-8-(trifluoromethyl)dibenzo[b,f][1,4]oxazepin-1- 1-yl)benzamide, or a pharmaceutically acceptable salt thereof. 46. The compound of claim 4 wherein the compound is (Z)-N-hydroxy-4-(3-morpholinodibenzo[b,f][1,4]oxazepin-11-yl)benzamide, or a pharmaceutically acceptable salt thereof. 47. The compound of claim 4 wherein the compound is (Z)-N-hydroxy-4-(4-propyldibenzo[b,f][1,4]oxazepin-11-yl)benzamide, or a pharmaceutically acceptable salt thereof. 48. The compound of claim 4 wherein the compound is (Z)-N-hydroxy-4-(4-(trifluoromethoxy)dibenzo[b,f][1,4]oxazepin-11-yl)benz- amide, or a pharmaceutically acceptable salt thereof. 49. The compound of claim 4 wherein the compound is (Z)-N-hydroxy-4-(6-methyldibenzo[b,f][1,4]oxazepin-11-yl)benzamide, or a pharmaceutically acceptable salt thereof. 50. The compound of claim 4 wherein the compound is (E)-4-(dibenzo[b,f][1,4]oxazepin-11-yl)-3-fluoro-N-hydroxybenzamide, or a pharmaceutically acceptable salt thereof. 51. The compound of claim 4 wherein the compound is (Z)-4-(4-fluorodibenzo[b,f][1,4]oxazepin-11-yl)-N-hydroxybenzamide, or a pharmaceutically acceptable salt thereof. 52. The compound of claim 4 wherein the compound is (E)-4-(2-(dibenzo[b,f][1,4]oxazepin-11-ylamino)ethyl)-N-hydroxybenzamide or a pharmaceutically acceptable salt thereof. 